Jeffrey M. Leiden is the CEO and Chairman of Vertex Pharmaceuticals, a company making waves in the biotech world with its innovative treatments. He stepped into the CEO role in February 2012 after joining Vertex as CEO Designee in late...

Jeffrey M. Leiden is the CEO and Chairman of Vertex Pharmaceuticals, a company making waves in the biotech world with its innovative treatments. He stepped into the CEO role in February 2012 after joining Vertex as CEO Designee in late 2011. Before Vertex, he was a Managing Director at Clarus Ventures, a venture capital firm, and before that, he held top roles at Abbott Laboratories. At Vertex, Dr. Leiden played a vital part in developing game-changing drugs for cystic fibrosis, transforming the company’s future. His financial stake in Vertex is strong, with more than $17 million in stock holdings as of early 2024, showing he believes deeply in the company’s mission. He made a big impact on Vertex's turnaround strategy and focuses on bringing new therapies to patients. Under his guidance, Vertex has become a leader in treating complex diseases which is reflected in both its market success and growth.